PE20231638A1 - COMPOUND FORMULATION FOR TREATMENT OF DIABETES MELLITUS TYPE 2 - Google Patents
COMPOUND FORMULATION FOR TREATMENT OF DIABETES MELLITUS TYPE 2Info
- Publication number
- PE20231638A1 PE20231638A1 PE2023000275A PE2023000275A PE20231638A1 PE 20231638 A1 PE20231638 A1 PE 20231638A1 PE 2023000275 A PE2023000275 A PE 2023000275A PE 2023000275 A PE2023000275 A PE 2023000275A PE 20231638 A1 PE20231638 A1 PE 20231638A1
- Authority
- PE
- Peru
- Prior art keywords
- diabetes mellitus
- treatment
- compound formulation
- type
- mellitus type
- Prior art date
Links
- 238000009472 formulation Methods 0.000 title abstract 3
- 239000000203 mixture Substances 0.000 title abstract 3
- 150000001875 compounds Chemical class 0.000 title abstract 2
- 201000000083 maturity-onset diabetes of the young type 1 Diseases 0.000 title 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 abstract 2
- ZWPRRQZNBDYKLH-VIFPVBQESA-N Gemigliptin Chemical compound C([C@@H](N)CC(=O)N1CC2=C(C(=NC(=N2)C(F)(F)F)C(F)(F)F)CC1)N1CC(F)(F)CCC1=O ZWPRRQZNBDYKLH-VIFPVBQESA-N 0.000 abstract 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 abstract 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 abstract 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 abstract 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 abstract 1
- 239000001913 cellulose Substances 0.000 abstract 1
- 229920002678 cellulose Polymers 0.000 abstract 1
- 235000010980 cellulose Nutrition 0.000 abstract 1
- 239000011248 coating agent Substances 0.000 abstract 1
- 239000006185 dispersion Substances 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 229960002458 gemigliptin Drugs 0.000 abstract 1
- 239000008103 glucose Substances 0.000 abstract 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 abstract 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 abstract 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 abstract 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 abstract 1
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical compound CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 abstract 1
- 229960003105 metformin Drugs 0.000 abstract 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 abstract 1
- 239000008108 microcrystalline cellulose Substances 0.000 abstract 1
- 229940016286 microcrystalline cellulose Drugs 0.000 abstract 1
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 1
- 229920002689 polyvinyl acetate Polymers 0.000 abstract 1
- 239000011118 polyvinyl acetate Substances 0.000 abstract 1
- 235000002906 tartaric acid Nutrition 0.000 abstract 1
- 239000011975 tartaric acid Substances 0.000 abstract 1
- 229940095064 tartrate Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
- A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
Refiere a una formulacion compuesta para el tratamiento de diabetes mellitus tipo 2. Dicha formulacion comprende una primera capa que incluye metformina, o clorhidrato como sal farmaceuticamente aceptable de la misma, una dispersion acuosa de acetato de polivinilo y un excipiente a base de celulosa, seleccionado de hidroxipropil metilcelulosa; y una segunda capa que incluye gemigliptina, o tartrato como una sal farmaceuticamente aceptable de la misma, acido tartarico y celulosa microcristalina como agente de recubrimiento. Ambas capas estan dispuestas en la forma de una tableta bicapa disenada para mejorar el cumplimiento de medicacion y la regulacion de glucosa en pacientes con diabetes mellitus tipo 2.Refers to a compound formulation for the treatment of type 2 diabetes mellitus. Said formulation comprises a first layer that includes metformin, or hydrochloride as a pharmaceutically acceptable salt thereof, an aqueous dispersion of polyvinyl acetate and a cellulose-based excipient, selected hydroxypropyl methylcellulose; and a second layer that includes gemigliptin, or tartrate as a pharmaceutically acceptable salt thereof, tartaric acid and microcrystalline cellulose as a coating agent. Both layers are arranged in the form of a bilayer tablet designed to improve medication compliance and glucose regulation in patients with type 2 diabetes mellitus.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/KR2020/010841 WO2022034944A1 (en) | 2020-08-14 | 2020-08-14 | Composite formulation for treatment of type 2 diabetes mellitus |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20231638A1 true PE20231638A1 (en) | 2023-10-16 |
Family
ID=80247912
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2023000275A PE20231638A1 (en) | 2020-08-14 | 2020-08-14 | COMPOUND FORMULATION FOR TREATMENT OF DIABETES MELLITUS TYPE 2 |
Country Status (6)
| Country | Link |
|---|---|
| BR (1) | BR112023002559A2 (en) |
| CL (1) | CL2023000415A1 (en) |
| CO (1) | CO2023002829A2 (en) |
| MX (1) | MX2023001785A (en) |
| PE (1) | PE20231638A1 (en) |
| WO (1) | WO2022034944A1 (en) |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8551524B2 (en) * | 2008-03-14 | 2013-10-08 | Iycus, Llc | Anti-diabetic combinations |
| WO2012049566A1 (en) * | 2010-10-14 | 2012-04-19 | Japan Tobacco Inc. | Combination therapy for use in treating diabetes |
| KR20130136718A (en) * | 2012-06-05 | 2013-12-13 | 한미약품 주식회사 | Sustained release and enteric metformin formulation and method for preparation thereof |
| UY35065A (en) * | 2012-10-08 | 2014-05-30 | Lg Life Sciences Ltd | COMBINED DRUG THAT INCLUDES GEMIGLIPTINE AND METFORMIN AND METHOD FOR PREPARATION |
| KR20180002460A (en) * | 2016-06-29 | 2018-01-08 | 주식회사 엘지화학 | Composition, kit and combination therapy for treating type 2 diabetes mellitus and diabetic dyslipidemia |
| KR102633770B1 (en) * | 2019-05-24 | 2024-02-02 | 주식회사 엘지화학 | Combination preparation for treating type 2 diabetes mellitus |
-
2020
- 2020-08-14 BR BR112023002559A patent/BR112023002559A2/en unknown
- 2020-08-14 MX MX2023001785A patent/MX2023001785A/en unknown
- 2020-08-14 WO PCT/KR2020/010841 patent/WO2022034944A1/en active Application Filing
- 2020-08-14 PE PE2023000275A patent/PE20231638A1/en unknown
-
2023
- 2023-02-10 CL CL2023000415A patent/CL2023000415A1/en unknown
- 2023-03-08 CO CONC2023/0002829A patent/CO2023002829A2/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2022034944A1 (en) | 2022-02-17 |
| BR112023002559A2 (en) | 2023-03-14 |
| MX2023001785A (en) | 2023-03-10 |
| CO2023002829A2 (en) | 2023-03-27 |
| CL2023000415A1 (en) | 2023-10-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2593582T3 (en) | Coated tablet formulation and method | |
| ES2356093T3 (en) | PHARMACEUTICAL COMBINATION THAT INCLUDES 3- (3-DIMETHYLAMINE-1-ETIL-2-METHYLPROPIL) PHENOL AND PARACETAMOL. | |
| PH12015502134A1 (en) | Mosapride sustained-release preparation for providing pharmacological and clinical effects with once-a-day administration | |
| US11759428B2 (en) | Pharmaceutical formulation comprising esomeprazole and sodium bicarbonate | |
| US20120100221A1 (en) | Pharmaceutical compositions containing a combination of an antihistamine and a decongestant | |
| HRP20171384T4 (en) | Pharmaceutical composition | |
| KR870003778A (en) | Manufacturing method of new drug | |
| EP1461018A2 (en) | Dual controlled release dosage form | |
| KR101526825B1 (en) | Pharmaceutical Compositions for The Treatment of Diabetes | |
| KR101526553B1 (en) | Combination drug comprising gemigliptin and metformin and method for the preparation thereof | |
| ES2977953T3 (en) | Compressed | |
| HRP20140390T1 (en) | Novel dosage form | |
| BR102016010170B1 (en) | STABLE PHARMACEUTICAL COMPOSITION WITH PROLONGED RELEASE | |
| JP2008542394A (en) | Controlled release composition of at least one form of venlafaxine | |
| WO2016050160A1 (en) | Paliperidone oral controlled-release tablet and preparation method thereof | |
| PE20231638A1 (en) | COMPOUND FORMULATION FOR TREATMENT OF DIABETES MELLITUS TYPE 2 | |
| CN106265583A (en) | A kind of 9-hydroxy-risperidone rate of release escalating formulation and preparation method thereof | |
| KR101497354B1 (en) | Slow release pharmaceutical composition having Eperisone as active ingredient | |
| ECSP23015569A (en) | COMPOUND FORMULATION FOR THE TREATMENT OF TYPE 2 DIABETES MELLITUS | |
| CN103284974B (en) | Benzene ring nonyl ester double-layer osmotic pump controlled-release tablet and preparation method thereof | |
| CN107913259A (en) | A kind of Metformin hydrochloride controlled release tablet and preparation method thereof | |
| KR20210099294A (en) | Hard Gelatin Capsule Comprising Enteric Coated Proton Pump Inhibitor and Sustained-Release Formulation Containing Mosapride | |
| KR101193495B1 (en) | Oral complex composition comprising pseudoephedrine and levocetirizine | |
| JP2006515607A5 (en) | ||
| KR20200135095A (en) | Combination preparation for treating type 2 diabetes mellitus |